Creating a registry for patients with neuroendocrine cervical cancer
Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix
This study is creating a database to gather information about patients with neuroendocrine cervical cancer to help improve understanding and treatment of this rare disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 750 (estimated) |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT04723095 on ClinicalTrials.gov |
What this trial studies
This study aims to collect and organize data on patients diagnosed with neuroendocrine carcinoma of the cervix, including various histologic subtypes. It will gather both retrospective and prospective information regarding disease characteristics, treatment regimens, and patient outcomes over a period of up to 10 years. The data will be stored in a secure repository to facilitate future research and enhance understanding of the disease's impact on patient health. By correlating clinical data with outcomes, the study seeks to improve knowledge and treatment strategies for this rare cancer.
Who should consider this trial
Good fit: Ideal candidates include patients with any subtype of neuroendocrine cervical carcinoma, regardless of their treatment stage.
Not a fit: Patients without a diagnosis of neuroendocrine cervical carcinoma or those who do not meet the inclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment options for patients with neuroendocrine cervical cancer.
How similar studies have performed: While this approach is focused on a specific cancer type, similar registries have shown success in enhancing understanding and treatment of other cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a personal history of cervical cancer with any portion of neuroendocrine component (including mixed tumors) of the following histologic subtypes: * Small cell neuroendocrine carcinoma * Large cell neuroendocrine carcinoma * Undifferentiated high-grade neuroendocrine carcinoma * Patients may be in any stage of treatment, surveillance or recurrence at the time of initial participation in the study * Patients with all stages of disease are considered eligible * Patients who do not speak English can be eligible if accompanied by an institutional interpreter * Patients who are receiving or have received treatment at any facility, including but not limited to M. D. Anderson Cancer Center are eligible * Patient may be residents of any country and be of any ethnic background * Patients who request to participate in the study, regardless of the method by which they learned of it, are eligible to participate, including, but not limited to patients who seek participation via the website * Next of kin or legal authorized representatives of patients who are deceased but had a history of neuroendocrine carcinoma (NEC) of the cervix are eligible to participate * Next of kin or legal authorized representatives of patients must read and speak English Exclusion Criteria: * Patients with other histologic subtypes of NEC of the cervix including typical and atypical carcinoid tumors
Where this trial is running
Houston, Texas
- M D Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Larissa A. Meyer — M.D. Anderson Cancer Center
- Study coordinator: Larissa A. Meyer, MD
- Email: lmeyer@mdanderson.org
- Phone: 713-745-0973
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.